Form D · Biotechnology
Perry Health, Inc.
San Francisco, CA · CIK 0001777621
Offering snapshot reported May 26, 2022 · SEC filing
- Reported sold
- $23.5M Offering amount: $23.5M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 17, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 26, 2022 | Initial | $23,462,311 | No comparison | 15 | SEC filing |
| May 24, 2019 | Initial | $2,550,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-447135
Total Offering Amount and Amount Sold includes the conversion of $5,462,317.11 in principal and interest of converting securities.
Source: Form D, filed May 26, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Arpan Chaudhury | Director, Executive, Promoter |
| Petar Petrov | Director |
| Jason Shuman | Director |
| Henry Toole | Director |
| Anshu Vaish | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1 Sansome Street Suite 3500
San Francisco, CA, 94104
San Francisco, CA, 94104